PURPOSE: Although uncommon, melanoma is associated with poor survival characteristics among African Americans and Hispanics compared with non-Hispanic whites (NHWs). Low socioeconomic status (SES) is also associated with poor survival among patients with melanoma, but it is not known whether this is because of SES itself or because of treatment disparities. We set out to determine this by using the large, population-based California Cancer Registry (CCR) database as a model. PATIENTS AND METHODS: We conducted a case-only analysis of CCR data (1993 to 2003), including a descriptive analysis of relevant clinical variables and SES. The SES variable used has been derived from principle component analysis of census block-level CCR data that was linked to census data to address seven indicators of SES. Univariate analyses of overall survival (OS) were conducted using the Kaplan-Meier method. Multivariate survival analyses were performed using Cox proportional hazard ratios (HRs). RESULTS: A total of 39,049 incident patient cases of cutaneous melanoma, including 36,694 in NHWs; 127 in African Americans; 1,996 in Hispanics; and 262 in Asian-Americans, were analyzed. Higher SES was associated with an early stage at presentation (P < .0001), with treatment with surgery (P = .0005), and with prolonged survival (P < .0001). After adjustments for age, sex, histology, American Joint Committee on Cancer stage, anatomic site, treatment, and SES, a statistically significant increased risk of death was observed for African Americans compared with NHWs (HR, 1.60; 95% CI, 1.17 to 2.18); no survival differences were noted for Asians or Hispanics compared with NHWs in the adjusted analysis. CONCLUSION: Low SES independently predicts poor outcome among patients with cutaneous melanoma. However, the poor OS observed for African American patients with melanoma is not explained by differences in treatment or SES.
PURPOSE: Although uncommon, melanoma is associated with poor survival characteristics among African Americans and Hispanics compared with non-Hispanic whites (NHWs). Low socioeconomic status (SES) is also associated with poor survival among patients with melanoma, but it is not known whether this is because of SES itself or because of treatment disparities. We set out to determine this by using the large, population-based California Cancer Registry (CCR) database as a model. PATIENTS AND METHODS: We conducted a case-only analysis of CCR data (1993 to 2003), including a descriptive analysis of relevant clinical variables and SES. The SES variable used has been derived from principle component analysis of census block-level CCR data that was linked to census data to address seven indicators of SES. Univariate analyses of overall survival (OS) were conducted using the Kaplan-Meier method. Multivariate survival analyses were performed using Cox proportional hazard ratios (HRs). RESULTS: A total of 39,049 incident patient cases of cutaneous melanoma, including 36,694 in NHWs; 127 in African Americans; 1,996 in Hispanics; and 262 in Asian-Americans, were analyzed. Higher SES was associated with an early stage at presentation (P < .0001), with treatment with surgery (P = .0005), and with prolonged survival (P < .0001). After adjustments for age, sex, histology, American Joint Committee on Cancer stage, anatomic site, treatment, and SES, a statistically significant increased risk of death was observed for African Americans compared with NHWs (HR, 1.60; 95% CI, 1.17 to 2.18); no survival differences were noted for Asians or Hispanics compared with NHWs in the adjusted analysis. CONCLUSION: Low SES independently predicts poor outcome among patients with cutaneous melanoma. However, the poor OS observed for African American patients with melanoma is not explained by differences in treatment or SES.
Authors: Ricardo A Pollitt; Christina A Clarke; Susan M Swetter; David H Peng; John Zadnick; Myles Cockburn Journal: Cancer Date: 2010-08-24 Impact factor: 6.860
Authors: Mario Mandalà; Gian Lorenzo Imberti; Dario Piazzalunga; Maurizio Belfiglio; Giuseppe Lucisano; Roberto Labianca; Lorenzo Marchesi; Barbara Merelli; Silvana Robone; Paola Poletti; Laura Milesi; Carlo Tondini Journal: Mayo Clin Proc Date: 2011-02 Impact factor: 7.616
Authors: Lori A Pollack; Jun Li; Zahava Berkowitz; Hannah K Weir; Xiao-Cheng Wu; Umed A Ajani; Donatus U Ekwueme; Chunyu Li; Brian P Pollack Journal: J Am Acad Dermatol Date: 2011-11 Impact factor: 11.527
Authors: Marianne Berwick; Anne S Reiner; Susan Paine; Bruce K Armstrong; Anne Kricker; Chris Goumas; Anne E Cust; Nancy E Thomas; Pamela A Groben; Lynn From; Klaus Busam; Irene Orlow; Loraine D Marrett; Richard P Gallagher; Stephen B Gruber; Hoda Anton-Culver; Stefano Rosso; Roberto Zanetti; Peter A Kanetsky; Terry Dwyer; Alison Venn; Julia Lee-Taylor; Colin B Begg Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-07-28 Impact factor: 4.254
Authors: Peter Brader; Kaitlyn Kelly; Sheng Gang; Jatin P Shah; Richard J Wong; Hedvig Hricak; Ronald G Blasberg; Yuman Fong; Ziv Gil Journal: PLoS One Date: 2009-03-10 Impact factor: 3.240
Authors: Jason A Zell; Walter Y Tsang; Thomas H Taylor; Rita S Mehta; Hoda Anton-Culver Journal: Breast Cancer Res Date: 2009-02-19 Impact factor: 6.466